for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cytokinetics, Inc.

CYTK.OQ

Latest Trade

18.96USD

Change

-0.84(-4.24%)

Volume

374,057

Today's Range

18.89

 - 

20.45

52 Week Range

8.02

 - 

30.06

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
19.80
Open
19.85
Volume
374,057
3M AVG Volume
21.92
Today's High
20.45
Today's Low
18.89
52 Week High
30.06
52 Week Low
8.02
Shares Out (MIL)
70.78
Market Cap (MIL)
1,341.97
Forward P/E
-11.09
Dividend (Yield %)
--

Next Event

Q4 2020 Cytokinetics Inc Earnings Release

Latest Developments

More

Cytokinetics Announces Results From Galactic-Hf Trial

Cytokinetics Reports Third Quarter 2020 Financial Results

Cytokinetics Inc Says Phase 3 Trial Of Omecamtiv Mecarbil Met Primary Composite Endpoint Of Reduction In Cardiovascular Death

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cytokinetics, Inc.

Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator; AMG 594, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Industry

Biotechnology & Drugs

Contact Info

280 E Grand Ave

SOUTH SAN FRANCISCO, CA

94080-4808

United States

+1.650.6243000

http://cytokinetics.com/

Executive Leadership

Leonard Patrick Gage

Independent Chairman of the Board

Robert I. Blum

President, Chief Executive Officer, Director

Ching Jaw

Chief Financial Officer, Senior Vice President

David W. Cragg

Chief Human Resource Officer, Chief Administrative Officer

Fady Ibraham Malik

Executive Vice President - Research and Development

Key Stats

2.11 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2017

-2.590

2018

-1.950

2019

-2.110

2020(E)

-1.710
Price To Earnings (TTM)
--
Price To Sales (TTM)
24.71
Price To Book (MRQ)
8.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
89.58
LT Debt To Equity (MRQ)
89.58
Return on Investment (TTM)
-37.23
Return on Equity (TTM)
-34.47

Latest News

Latest News

BRIEF-FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure

* FDA GRANTS FAST TRACK DESIGNATION FOR OMECAMTIV MECARBIL IN HEART FAILURE

BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.66

* Q1 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA

BRIEF-Cytokinetics - Co, Astellas Pharma Entered Two Agreements, Which Amend And Restate Co's Research, Development Commercialization Collaboration

* CYTOKINETICS - CO, ASTELLAS PHARMA INC. ENTERED TWO AGREEMENTS, WHICH AMEND AND RESTATE CO'S RESEARCH, DEVELOPMENT COMMERCIALIZATION COLLABORATION

BRIEF-Cytokinetics Says Co Believes It Is On Track To Achieve Its Key Strategic Objectives For 2020

* CYTOKINETICS PROVIDES CLINICAL TRIALS AND BUSINESS UPDATE IN RESPONSE TO COVID-19 PANDEMIC

BRIEF-Cytokinetics Granted European Orphan Designation For Reldesemtiv For The Treatment Of Amyotrophic Lateral Sclerosis

* CYTOKINETICS GRANTED EUROPEAN ORPHAN DESIGNATION FOR RELDESEMTIV FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics Reports Q4 Loss Per Share $0.52

* Q4 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA

BRIEF-Cytokinetics Announces Preclinical Data For AMG 594 Presented At Keystone Symposium On Heart Failure

* CYTOKINETICS ANNOUNCES PRECLINICAL DATA FOR AMG 594 PRESENTED AT THE KEYSTONE SYMPOSIUM ON HEART FAILURE

BRIEF-Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

* AMGEN, CYTOKINETICS AND SERVIER ANNOUNCE CONTINUATION OF GALACTIC-HF FOLLOWING PLANNED INTERIM ANALYSIS

BRIEF-Cytokinetics And Cure SMA Renew And Expand Partnership To Advance Education And Awareness Of SMA

* CYTOKINETICS AND CURE SMA RENEW AND EXPAND PARTNERSHIP TO ADVANCE EDUCATION AND AWARENESS OF SMA

BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.56

* CYTOKINETICS, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75

* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up